<DOC>
	<DOCNO>NCT02854839</DOCNO>
	<brief_summary>The propose study evaluate safety efficacy MG4101 ( allogeneic Natural killer cell ) patient hepatocellular carcinoma ( HCC ) transarterial chemoembolization ( TACE ) .</brief_summary>
	<brief_title>A Study MG4101 ( Allogeneic Natural Killer Cell ) Intermediate-stage Hepatocellular Carcinoma</brief_title>
	<detailed_description>This randomize , multi-center , open-labeled , Phase 2a study patient HCC transarterial chemoembolization ( TACE ) . A total 78 patient randomize ( 1:1 ) one two group , receive adjuvant therapy use MG4101 ( allogeneic Natural killer cell , Treatment group ) adjuvant therapy ( Control group ) . Patients assign Treatment group receive 2 cycle MG4101 ( cycle 3 treatment frequency per week , cycle 3 week withdrawal period ) . After treatment period , patient undergo follow progression survival every 12 week ( ± 7 day ) follow 1 year last patient ` enrollment date . The Control group ` patient undergo follow progression survival every 12 week ( ± 7 day ) follow 1 year last patient ` enrollment date .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Inclusion criterion 1 . Patients 20 80 year age 2 . Life expectancy &gt; 12 week 3 . Patients complete remission accord mRECIST Dynamic contrastenhanced 3 4phase CT tissue biopsy Patients diagnose Hepatocellular Carcinoma BCLC stage B TACE . Dynamic contrastenhanced CT must within 4 week TACE . 4 . Previous TACE following : Lipiodol mixed chemotherapy ( adriamycin etc . ) Used Gelatin sponge Polyvinyl alcohol microsphere . 5 . Patients local treatment Resection , Radiofrequency Ablation , Percutaneous ethanol injection Transarterial chemoembolization participates study . 6 . Patients whose ChildPugh score less B8 . 7 . Patients whose ECOG score 0 8 . Patients satisfy follow condition blood test , kidney function test , liver function test . Absolute neutrophil count ≥ 1,000 x 10^6 /L hemoglobin level ≥ 8.5 g/㎗ platelet count ≥ 50,000 /㎣ Total bilirubin &lt; 3.0 ㎎/㎗ Serum creatinine ≤ 1.5 x upper normal limit ( UNL ) Total Albumin ≥ 2.8 ㎎/㎗ 9 . Able willing provide write informed consent comply study protocol . Exclusion criteria 1 . Patients metastasis . 2 . Patients Portal vein hepatic vein invasion . 3 . Patient medical history following : Patients Living donor Liver Transplantation Orthotopic liver transplantation . Patients receive anticancer chemotherapy 4 week prior study . Patients recover adverse reaction prior study . Patients receive external beam radiation liver , immunotherapy , cell therapy , target therapy . Prior use systemic anticancer chemotherapy twice . 4 . Patients history malignant tumor 5 year prior study exception Carcinoma situ.. 5 . Patients history autoimmune disease Rheumatoid arthritis , systemic Lupus Erythematosus , Vasculitis , Multiple sclerosis , Adolescent Insulindependent Diabetes Mellitus , etc . 6 . Patients history human immunodeficiency virus ( HIV ) infection . 7 . Patients participate clinical trial within 4 week prior study . 8 . Patients treat immunosuppressant 3 month prior study . 9 . Patients condition uncontrolled need treatment . 10 . Pregnant breastfeeding subject .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>